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334P Health related quality of life in women with HR1/HER2- advanced or
metastatic breast cancer treated in real world settings in Italy and
Germany
M. De Laurentiis1, A. Ko¨nig2, K.L. Davis3, D. Mitra4, C.M.A. Nuzzo5, M. Ajmera3, S. de
Placido6, S. Brucker7, N. Harbeck2
1Department of Breast and Thoracic Oncology, National Cancer Institute "Fondazione
Pascale", Naples, Italy, 2Department of Obstetrics and Gynecology, Brustzentrum der
Universitaet Muenchen (LMU), Munich, Germany, 3Health Economics, RTI Health
Solutions, Research Triangle Park, NC, USA, 4Patient Health & Impact, Pfizer Inc, New
York, NY, USA, 5Pfizer Oncology, Pfizer Inc, Rome, Italy, 6Department of Clinical
Medicine and Surgery, University of Naples Federico II, Naples, Italy, 7Department of
Obstetrics and Gynecology, Tu¨bingen University Hospital, Tu¨bingen, Germany
Background: Real-world data on health-related quality of life (HRQoL) in women
with HRþ/HER2- advanced/metastatic breast cancer (ABC/mBC) are limited. This
study aims to address this gap.
Methods:MARIA is a non-interventional, prospective, multi-center study that
includes women in Italy and Germany initiating their first or second therapy in the
HRþ/ HER2- ABC/mBC setting. Breast cancer specific HRQoL was assessed using the
Functional Assessment of Cancer Therapy-Breast (FACT-B).We report baseline clini-
cal characteristics and HRQoL assessments at enrollment (baseline) and at 3 and 6
months for the first 262 patients enrolled. Change from baseline was calculated for
patients with both baseline and follow-upmeasurement and tested for statistical signifi-
cance using t-tests for the overall cohort and within subgroups stratified by visceral and
bonemetastases status.
Results:Median age was 61 years and 46% had visceral disease. At enrollment, 32%
were receiving endocrine monotherapy, 34% chemotherapy alone, 28% endocrine/ tar-
geted therapy combinations, and 7% other regimens. A statistically significant
(p< 0.05) deterioration was observed in the overall cohort at Month 3 for both FACT-
B (-4.9 [14.9]) and FACT-G (-4.1 [13.2]) and atMonth 6 for the total FACT-G score (-
2.1 [12.7]). In the subgroup with visceral and bone metastases, a statistically significant
(p< 0.05) deterioration was observed in FACT-G scores at 3 months: (-6.6 [16.1]) and
at 6 months (-3.6 [12.3]) while no significant change was observed in FACT-B scores. A
statistically significant (p< 0.05) deterioration from baseline was observed in the sub-
group with visceral disease and without bonemetastases in FACT- B score at 3 months
(mean [SD]: -6.7 [13.9] and at 6 months (-3.9 [16.6]), respectively while no significant
change was observed in FACT-G scores.
Conclusions: A statistically significant deterioration was observed in HRQOL scores at
some time points after initiating a new line of therapy in the overall cohort and some
subgroups of HRþHER2-MBC patients in a prospective study In Italy and Germany.
Further follow-up is ongoing to examine the longer-term impact of therapy on
HRQoL.
Legal entity responsible for the study: Pfizer Inc.
Funding: Pfizer Inc.
Disclosure:M.De Laurentiis: Honoraria; Pfizer, Novartis, Roche, Celgene, AstraZeneca,
Eisai, Eli Lilly. K.L. Davis, M. Ajmera: Employee: RTIHealth Solutions, whowere paid
consultants to Pfizer in connectionwith the development of this abstract. D.Mitra,
C.M.A. Nuzzo: Employment and stock ownership: Pfizer. N. Harbeck:Honoraria: Lilly,
Novartis, Pfizer. All other authors have declared no conflicts of interest.
335P Breast cancer (BC) treatment (tx) with everolimus (EVE) and
exemestane (EXE) in hormone receptor positive (HR1)/ HER2-negative
(HER22) postmenopausal women: Final analysis of the French
observational TANGO study
C. Villanueva1, G. Yazbek2, P. Beuzeboc3, E. Viel4, N. Dohollou5, E. Luporsi6, J-
C. Eymard7, E. Levy8, M-A. Mouret-Reynier9, L-M. Dourthe10, E. Malaurie11,
M. Madelenat12, A. Denden12, E-C. Antoine13
1Medical Oncology, Centre de Cance´rologie du Grand Montpellier, Montpellier, France,
2Service d’Oncologie Me´dicale, Institut Jean Godinot, Reims, France, 3Medical Oncology,
Hoˆpital Foch, Suresnes, France, 4Medical Oncology, Cabinet D’Oncologie Me´dicale,
Chalon-sur-Saoˆne, France, 5Medical Oncology, Polyclinique Bordeaux Nord Aquitaine,
Bordeaux, France, 6Medical Oncology, Hopital de Mercy – CHR Metz Thionville, Ars
Laquenexy, France, 7Medical Oncology, Institut Jean Godinot, Reims, France, 8Medical
Oncology, Clinique Bizet, Paris, France, 9Medical Oncology, Centre Jean Perrin,
Clermont-Ferrand, France, 10Medical Oncology, Clinique Sainte-Anne, Strasbourg,
France, 11Medical Oncology, CHI de Cre´teil, Cre´teil, France, 12Medical Oncology,
Novartis Pharma S.A.S., Rueil-Malmaison, France, 13Medical Oncology, Clinique
Hartmann, Neuilly-sur-Seine, France
Background: TANGO is a French observational prospective study of women with
advanced BC treated with EVE/EXE. Themain objective was to describe the manage-
ment of stomatitis and noninfectious pneumonitis (NIP) in clinical practice. Overall
safety, duration of EVE/EXE tx and progression-free survival (PFS) were also assessed.
Methods: Eligible patients (pts) were postmenopausal women18 years with
advanced HRþ/HER2 BC, for whom EVE/EXE was initiated. Statistical analyses were
mainly descriptive. Tx duration and PFS were estimated with Kaplan-Meier methods.
Results: FromNov 2014 toMar 2016, 596 pts had received EVE/EXE (Pts characteris-
tics: see table).
Table: 335P Pts baseline characteristics at EVE/EXE initiation
Pts who
received EVE/EXE
(N¼ 596)
Age
Mean (standard deviation) age, years 65.1 (10.8)
Pts aged 75 years – n (%) 131 (22%)
Median (range) time since initial BC diagnosis
to inclusion, years
7.5 (0.1 44.3)
Pts with de novo metastatic BC at diagnosis n (%) 145 (24%)
Pts with ECOG 1 n (%) 527 (88%)
Metastases
Pts with bone-only metastases – n (%) 199 (33%)
Pts with visceral metastases – n (%) 290 (49%)
Previous lines of tx for metastatic disease
Pts without previous line – n (%) 113 (19%)
Pts with 1 previous line – n (%) 208 (35%)
Pts with 2 previous lines – n (%) 126 (21%)
Pts with 3 previous lines – n (%) 149 (25%)
BC relapses relative to adjuvant hormonal tx
(N, available data)
375
<2 years after the beginning of tx – n (%) 57 (15%)
2 years after the beginning of tx and
<1 year after the end of tx – n (%)
165 (44%)
1 year after the end of tx – n (%) 142 (38%)
305 pts (51%) experienced stomatitis and 80 (13%) experienced NIP (median time to
1st event [range]: 21 [1 333] and 104 days [1 396], respectively). Most stomatitis
(87%) and NIP (91%) were grade 1-2. Stomatitis were mainly treated with mouth-
washes (77%), topical analgesics (19%) and antifungals (15%), and NIP with cortico-
steroids (40%) and antibiotics (10%). 509 pts (85%) had EVE-related adverse events
(AE), the most common (excluding stomatitis/NIP) being asthenia (19%), diarrhoea
(11%) and rash (10%). 90 pts (15%) had EVE-related serious AE, the most common
(excluding stomatitis/NIP) being asthenia (2%). 5 pts (<1%) had EVE-related fatal
AE: health deterioration, multiple organ failure, epistaxis, interstitial lung disease, pleu-
ral metastases and disorientation.With 562 analysed pts, the median PFS was 6.9
months (95% confidence interval [CI]: 6.2 7.8) andmedian duration of EVE/EXE tx
was 5.3 months (95% CI: 4.8 6.0). After EVE discontinuation, most pts continued
EXE alone (55%) or had chemotherapy (8%).
Conclusions: Results from this real-life observational study reinforce the known safety
profile of EVE and better characterize stomatitis and NIP, as well as their management
in EVEtreated pts.
Clinical trial identification: EU PAS: EUPAS7325.
Editorial acknowledgement: Florence Arts and Je´roˆme Leemans; Keyrus Biopharma,
Belgium.
Legal entity responsible for the study:Novartis Pharma S.A.S. (France).
Funding:Novartis Pharma S.A.S. (France).
Disclosure:C.Villanueva, E.-C. Antoine: Investigator and Scientific Committeemember
on this study sponsored byNovartis Pharma S.A.S. G. Yazbek, P. Beuzeboc, N. Dohollou,
E. Luporsi, E. Levy; L.-M.Dourthe, E.Malaurie: Investigator on this study sponsored by
Novartis Pharma S.A.S. E. Viel: Investigator on this study sponsored byNovartis Pharma
S.A.S; Advisory boards: Bristol-Myers Squibb and Sanofi. J-C. Eymard,M-A.Mouret-
Reynier: Investigator on this study sponsored byNovartis Pharma S.A.S; Advisory boards:
Novartis Pharma S.A.S.M.Madelenat, A.Denden: Employee: Novartis Pharma S.A.S.
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1Oncology, Western University, London Regional Cancer Program, London, ON,
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Background: Everolimus (E) plus exemestane are approved for advanced hormone
receptor (þ) breast cancer (BC) after progression on non-steroidal aromatase inhibi-
tors. The role of E is less well defined in other BC phenotypes and with other drugs.
We conducted a systematic review andmeta-analysis to assess the efficacy and safety of
adding E to standard of care (SoC) in advanced BC regardless of tumor phenotype and
treatment type.
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Methods: The electronic databases PubMed and EMBASE, were searched for eligible
randomized trials. Pooled hazard ratios (HR) for progression free survival (PFS) and
overall survival (OS) and pooled risk ratios (RR) and odds ratios (OR) for objective
response rates (ORR), clinical benefit rates (CBR) and grade 3 or higher toxicity were
meta-analyzed using the generic inverse variance, theMantel-Henszel and Peto
method. To account for between-studies heterogeneity, random-effect models were
used. Subgroup analyses compared survival outcomes by tumor phenotype.
Results:Data of 2,693 patients from 7 trials were analyzed. The addition of E to the SoC
reduced the risk of disease progression by 33% (7 trials, HR 0.67, 95%CI 0.52-0.86).
This did not translate into an OS benefit (4 trials, HR 0.91, 95%CI 0.62-1.33). In addi-
tion, E improved the ORR (6 trials, RR 0.91, 95%CI 0.85-0.97) and CBR (7 trials, RR
0.79 95%CI 0.65-0.97) while it increased the risk of developing grade 3 toxicity
including stomatitis (OR 5.00, 95%CI 3.63-6.89) and pneumonitis (OR 3.13, 95%CI
1.83-5.36). The PFS benefit was more prominent for patients with hormone receptor
(þ) / HER2 (-) (HR 0.51, 95%CI 0.43-0.59) than HER2 (þ) disease (HR 0.83, 95%CI
0.73-0.96; p for subgroup differences<0.001). For the HER2 (þ) subgroup, the PFS
benefit was restricted to hormone receptor (-) patients (HR 0.65, 95%CI 0.53-0.81 and
HR 0.99, 95%CI 0.83-1.19 for hormone receptor (þ) patients; p for subgroup differen-
ces 0.004).
Conclusions: E reduces the risk of disease progression in hormone receptor (þ)
advanced BC independent of endocrine therapy type. In HER2 (þ) patients, the benefit
is limited for hormone receptor (-) patients. Given the use of newer drugs in the first
line, real-world data are needed to confirm whether the benefit persists for patients
who develop resistance to CDK4/6 inhibitors.
Legal entity responsible for the study: Jacques Raphael.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
337P First-line treatment for endocrine sensitive bone-only metastatic
breast cancer: Is more always better?
A. Toss1, M. Venturelli1, I. Sperduti2, C. Isca1, E. Barbieri1, F. Piacentini1, C. Omarini1,
L. Cortesi1, S. Cascinu1, L. Moscetti1
1Department of Oncology and Haematology, Azienda Ospedaliero - Universitaria
Policlinico di Modena, Modena, Italy, 2Bio-Statistics Unit, IRCCS Regina Elena National
Cancer Institute, IRCCS Regina Elena National Cancer Institute, Rome, Italy
Background: The standard first-line for endocrine sensitive metastatic breast cancer
(BC) is represented by endocrine therapy. Several phase III clinical trials searched for
more effective strategies. The SWOG, FACT and FALCON trials analyzed the role of
Fulvestrant (Fv), producing contradictory results. TheMonaleesa2, Monaleesa7,
Monarch3 and Paloma2 trials showed that the addition of a CDK4/6 inhibitor to an
aromatase inhibitor (AI) increases the PFS. The use of the combination for the first-line
treatment of bone-only disease (BoD) is widely discussed. Our meta-analysis aims to
explore the role of the new endocrine strategies in BoD.
Methods: The Prisma statement was used. A systematic review of electronic databases
identified the phase III clinical trials comparing the standard AI to a novel experimental
strategy. The hazard ratios (HR) for PFS for the subgroup of BoD were pooled in a
meta-analysis. The heterogeneity of the data was evaluated by Chi-square Q test and I2
statistic.
Results: 7 studies were included in the analyses. 4 trials explored the role of CDK4/6
inhibitors (Monaleesa2 and 7,Monarch3 and Paloma2), 2 trials analyzed FvþAI
(SWOG and FACT), while one trial studied Fvmonotherapy (FALCON). 5 trials
reported data regarding the BoD, while 2 trials included the BoD in the non-visceral
disease. Overall, the meta-analyses showed a PFS advantage for the experimental arms
[HR 0.67 p 0.01], with a significant moderate/high heterogeneity [I2 69.88% p 0.003].
Only the FALCON and Paloma2 showed a significant improvement in PFS, respectively
for Fv and Palbociclibþ Letrozole. Considering only trials reporting data for BoD, the
experimental arms significantly improved the PFS [HR 0.60 p 0.001], with a low/mod-
erate non-significant heterogeneity [I2 37.73% p 0.17].
Conclusions: The meta-analyses of trials reporting data for BoD, showed that the novel
strategies are able to improve the PFS. Nonetheless, only Palbociclibþ Letrozole pro-
vided statistically significant data of advantage in this setting. In clinical trials, BoD is
often included in the non-visceral disease subgroup. Future clinical trials should take
into account the differences in natural history and better prognosis of BoD, in order to
define the best approach to these patients.
Legal entity responsible for the study: Angela Toss.
Funding:Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
338P Real world treatment patterns associated with palbociclib combination
therapy in Germany: Results from the IRIS study
D. Mitra1, G. Taylor-Stokes2, J. Waller3, K. Gibson3, G. Milligan4, S. Iyer1
1Patient Health & Impact, Pfizer Inc., New York, NY, USA, 2Oncology, Adelphi Real
World, Bollington, UK, 3Observational Research, Adelphi Real World, Bollington, UK,
4Statistics, Adelphi Real World, Bollington, UK
Background: Following the approval of palbociclib as the first CDK4/6 inhibitor for
HRþ/HER2- advanced/metastatic breast cancer (ABC/MBC), a need exists to under-
stand treatment patterns associated with palbociclib combination therapies in real
world clinical settings. The Ibrance RealWorld Insights (IRIS) study aims to address
this evidence gap.
Methods: A retrospective chart review of HRþ/HER2- ABC/MBC patients who
received palbociclib combination therapies was conducted in Germany. Physicians
completed electronic case report forms (eCFRs), extracting data on patient demo-
graphics, clinical characteristics and treatment patterns from an index date (60 days
after physician’s first prescription of palbociclib) until the most recent record available.
Results: 42 physicians completed 257 eCRFs with 48% representing academic centers.
Themean (SD) age of patients at palbociclib initiation was 59.6 (9.4) years (median, 60
years). ECOG status at palbociclib initiation was mostly 0 (48.2%) or 1 (33.5%).
Visceral disease was present in 65.6% of patients. Approximately 75% of patients
received palbociclib in combination with aromatase inhibitors (AI) and 25% in combi-
nation with fulvestrant. Overall, 97% patients received palbociclibþ AI as 1st line
advanced therapy, the remaining having received chemotherapy previously in the
advanced setting. Letrozole was the most common AI partner therapy (63.4%) followed
by anastrozole (23.2%), and exemestane (13.4%). Palbociclibþ fulvestrant was mostly
used in first (44.4%) and second (52.4%) lines. The most frequently prescribed starting
dose was 125mg/day (73.2%), followed by 100mg/day (26.1%) and 75mg/day (0.8%).
76% of palbociclibþ AI patients started on 125mg compared to 65% of palbociclibþ
fulvestrant patients. Dose reductions occurred in only 28 (10.9%) patients (7.4% of
those who started at 125mg/day) and a cycle delay occurred in 1 (3.4%) patient. Dose
reduction rates were 10.8% in palbociclibþAI and 11.1% in palbociclibþ fulvestrant.
Conclusions: In the real world setting, rates of dose reduction were low, and were simi-
lar between palbociclibþ AI and palbociclibþ fulvestrant in HRþ/HER2- ABC/MBC
patients in Germany.
Legal entity responsible for the study: Pfizer Inc.
Funding: Pfizer Inc.
Disclosure:D.Mitra: Employment and stock ownership: Pfizer. G. Taylor-Stokes, J.
Waller, K. Gibson, G. Milligan: Employee: Adelphi RealWorld, who were paid consul-
tants to Pfizer in connection with the development of this abstract. S. Iyer:
Employment and stock ownership at Pfizer.
339P Management of abemaciclib associated adverse events in patients
with hormone receptor positive (HR1), HER2- advanced breast cancer:
Analysis of the MONARCH trials
H.S. Rugo1, S.M. Tolaney2, J. Huober3, M. Toi4, V. Andre´5, S. Barriga6, T. Forrester7,
G.W. Sledge8, M.P. Goetz9
1Breast Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, San
Francisco, CA, USA, 2Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,
3Gynecol. & Obstetrics, Universitaetsfrauenklinik Ulm, Ulm, Germany, 4Breast Surgery,
Kyoto University-Graduate School of Medicine, Kyoto, Japan, 5Oncology, Eli Lilly and
Company, Paris, France, 6Oncology, Eli Lilly and Company, Madrid, Spain, 7Oncology,
Eli Lilly and Company, Indianapolis, IN, USA, 8Medical Oncology, Stanford University,
Stanford, CA, USA, 9Alliance Foundation for Clinical Trials in Oncology, Mayo Clinic,
Rochester, NY, USA
Background: Abemaciclib is a CDK4 & 6 inhibitor dosed continuously with demon-
strated efficacy and an acceptable safety profile in pts with HRþ, HER2-negative
advanced breast cancer as monotherapy (MONARCH 1) and in combination with
endocrine therapy; with fulvestrant (MONARCH 2) or with non-steroidal aromatase
inhibitors (MONARCH 3). Themost frequent adverse event (AE) is low-grade diar-
rhea; neutropenia is the most frequent grade 3/4 AE.We describe the timing andman-
agement of common AEs in theMONARCH trials.
Methods: Enrollment criteria, study designs and key eligibility criteria of MONARCH
1, 2 and 3 have been reported (Dickler et al. 2017; Sledge et al. 2017; Goetz et al. 2017).
Pts were advised to initiate antidiarrheal therapy at first sign of diarrhea and notify the
investigator, drink fluids. If not improved within 24 hours to< grade 1, treatment was
suspended until diarrhea resolved. Dose reductions required for grade3 or persistent
grade 2 diarrhea. For grade 3 neutropenia, abemaciclib was held until< grade 2. The
dose was reduced for recurrent grade 3 or grade 4 neutropenia.
Results:Across MONARCH, the median time to onset of diarrhea was between day 6-
8. First dose reductions for diarrhea occurred at a median of 28-41 days. Dose holds for
diarrhea were brief, constituting 1.7-3.8% off total treatment time. The median time to
onset of grade 3/4 neutropenia was 29-36.5 days, and resolved at a median of 11-15
days. AEs were managed by dose adjustments and/or supportive medication (Table).
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